Published in Front Immunol on April 23, 2014
A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis. PLoS One (2014) 0.85
Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine. Clin Exp Vaccine Res (2015) 0.79
Identification of Novel Potential Vaccine Candidates against Tuberculosis Based on Reverse Vaccinology. Biomed Res Int (2015) 0.78
Vaccine-mediated immunity to experimental Mycobacterium tuberculosis is not impaired in the absence of Toll-like receptor 9. Cell Immunol (2015) 0.76
Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development. Front Immunol (2017) 0.75
Significance of antigen and epitope specificity in tuberculosis. Front Immunol (2014) 0.75
Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K. Sci Rep (2017) 0.75
Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go? Hum Vaccin Immunother (2016) 0.75
A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis. Hum Vaccin Immunother (2016) 0.75
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med (2000) 9.78
Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science (1999) 8.63
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity (1998) 8.29
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
CD36 is a sensor of diacylglycerides. Nature (2005) 5.20
The immune response in tuberculosis. Annu Rev Immunol (2013) 3.91
Immunological mechanisms of vaccination. Nat Immunol (2011) 3.35
Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med (2003) 3.21
Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med (2009) 3.19
Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest (2005) 3.19
Key roles of adjuvants in modern vaccines. Nat Med (2013) 2.62
Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol (2010) 2.38
Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med (1996) 2.36
Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med (2012) 2.33
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
Adjuvants--a balance between toxicity and adjuvanticity. Vaccine (1993) 1.86
Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol (2005) 1.84
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta (2005) 1.81
Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines (2011) 1.75
Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res (2002) 1.62
TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol (2009) 1.61
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 1.60
Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol (2005) 1.58
Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun (2004) 1.49
CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity (2001) 1.47
New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol (2012) 1.40
The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol (2012) 1.39
Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol (2004) 1.31
Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun (2004) 1.28
Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol (2006) 1.28
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release (2013) 1.25
Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett (2011) 1.25
Tuberculosis vaccines: time to think about the next generation. Semin Immunol (2013) 1.23
Modern subunit vaccines: development, components, and research opportunities. ChemMedChem (2013) 1.22
T-cell epitope vaccine design by immunoinformatics. Open Biol (2013) 1.20
Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine (2006) 1.20
Identification of stimulating and inhibitory epitopes within the heat shock protein 70 molecule that modulate cytokine production and maturation of dendritic cells. J Immunol (2005) 1.17
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol (2007) 1.14
Immune response against heat shock proteins in infectious diseases. Immunobiology (1999) 1.12
The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res (1998) 1.12
Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines (2011) 1.06
Mechanisms of action of adjuvants. Front Immunol (2013) 1.05
The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS One (2013) 1.02
Mycobacterial heat shock protein 70 induces interleukin-10 production: immunomodulation of synovial cell cytokine profile and dendritic cell maturation. Clin Exp Immunol (2004) 1.02
Vaccine development for tuberculosis: current progress. Drugs (2013) 1.01
Cell surface receptors for molecular chaperones. Methods (2007) 0.99
Flagellin as a good carrier and potent adjuvant for Th1 response: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen. Mol Immunol (2008) 0.98
Role of interleukin-12 family cytokines in the cellular response to mycobacterial disease. Int J Infect Dis (2009) 0.98
Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol (2010) 0.96
Adjuvant activity of cytokines. Methods Mol Biol (2010) 0.96
The mycobacterial cord factor adjuvant analogue trehalose-6,6'-dibehenate (TDB) activates the Nlrp3 inflammasome. Immunobiology (2012) 0.96
Prolonged survival of allografts induced by mycobacterial Hsp70 is dependent on CD4+CD25+ regulatory T cells. PLoS One (2010) 0.95
Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur J Immunol (2008) 0.95
Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity. Biochem Soc Trans (2004) 0.93
Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response. J Infect Dis (2011) 0.92
Review: Toll-like receptors and NOD-like receptors in pulmonary antibacterial immunity. Innate Immun (2010) 0.92
Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A. Immunol Lett (2007) 0.92
The knowns and unknowns of the immunopathogenesis of tuberculosis. Int J Tuberc Lung Dis (2012) 0.89
Mode of action of adjuvants: implications for vaccine safety and design. Biologicals (2010) 0.89
Development of a secondary immune response to Mycobacterium tuberculosis is independent of Toll-like receptor 2. Infect Immun (2010) 0.88
The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis (Edinb) (2012) 0.88
Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major. Infect Immun (2002) 0.88
TLR2 looks at lipoproteins. Immunity (2009) 0.85
Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis. J Infect Dis (2008) 0.85
Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein. Microbiol Immunol (2011) 0.83
Immunological properties of recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing fusion protein IL-2-ESAT-6. Acta Biochim Biophys Sin (Shanghai) (2006) 0.83
A novel recombinant Mycobacterium bovis bacillus Calmette-Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity. Acta Biochim Biophys Sin (Shanghai) (2011) 0.82
Cell-mediated immune responses and protective efficacy against infection with Mycobacterium tuberculosis induced by Hsp65 and hIL-2 fusion protein in mice. Scand J Immunol (2008) 0.81
Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70. Biologicals (2011) 0.79
New studies of BCG: implications for tuberculosis vaccines. Lancet Infect Dis (2011) 0.76